Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

INTRODUCTION: Although PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecule expressed in T cells, which could enhance T c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yichen, Zhang, Xuyao, Xu, Caili, Nan, Yanyang, Fan, Jiajun, Zeng, Xian, Kwon, Byoung S., Ju, Dianwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762552/
https://www.ncbi.nlm.nih.gov/pubmed/36544785
http://dx.doi.org/10.3389/fimmu.2022.1004475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762552/
https://www.ncbi.nlm.nih.gov/pubmed/36544785
http://dx.doi.org/10.3389/fimmu.2022.1004475

Ejemplares similares